PHAXIAM develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics.

The phages (or bacteriophages) are harmless to human organisms and specifically eradicate bacteria in an ultra-targeted way to fight microbial infections. They offer excellent efficacy against bacteria – including bacteria that are multi-resistant to antibiotics –, are very well tolerated due to their high specificity and adapt very quickly to bacterial mutations while respecting microbiota, unlike antibiotics.

Severe resistance infections are a major global public health problem, responsible today for over 1 million deaths a year worldwide, and which could, according to the World Health Organization, cause 10 million deaths a year by 2050 if nothing is done.

The growing threat of antibiotic resistance has been the main driver of the focus on developing alternative treatments, including bacteriophages.